Pharmacy Hazardous Compounding Contingency Southern Nevada Health Care System

The Department of Veterans Affairs Southern Nevada Healthcare System is seeking a vendor under a firm fixed price contingency contract to compound and deliver antineoplastic hazardous drugs from an FDA 503A compliant facility to support chemotherapy infusion services for up to 15 patients per day, Monday through Friday, year-round. The contract period runs from October 1, 2026, through September 30, 2031, with deliveries required at the North Las Vegas VA Medical Center Pharmacy. All compounding, labeling, and beyond-use dating must strictly adhere to USP 797, USP 800, and federal regulations, with medications delivered with at least 12 hours of remaining beyond-use dating. Orders submitted by 12:00 p.m. PST must be delivered the next business day, while late orders are considered STAT and may incur additional charges; all orders must be placed via secure network or fax and followed by a phone call. The vendor must provide an itemized price list for all compounded medications including but not limited to Abraxane, Bevacizumab, Docetaxel, and Actemra, with pricing based on an estimated annual volume but no stated contract ceiling. Medications must be stored and used in accordance with FDA-approved labeling, and the vendor is required to notify the VA of any anticipated shortages, recalls, or discontinuations. All services must comply with VA Pharmacy Benefits Management guidelines and federal security requirements, including the use of VA-approved encryption for sensitive information and adherence to FIPS 140-2 standards. The contractor is prohibited from accessing any VA desktop computers or online resources and must handle all VA information in full compliance with applicable federal and VA data protection laws. Invoices must be submitted electronically through the VA’s Tungsten system upon delivery and government acceptance, with no advance payments authorized; each invoice must include the contract number, purchase order number, itemized costs for drugs and materials, and date of service. Evaluation of responses will be based on a comparative process under FAR 13.106-2(b)(3), with technical compliance as the primary factor and price as secondary; failure to meet minimum requirements such as USP standards, delivery timelines, or documentation will result in elimination. Only the Contracting Officer, Leah Smith, may modify the contract, and the vendor must respond to complaints within three working days and maintain complete records of all complaints for inspection. The solicitation, issued as a combined commercial products and services procurement